Tempus expands multi-year collaboration with Moderna and Merck
The collaboration centers on intismeran autogene, being evaluated with KEYTRUDA in patients with completely resected stage IIB-IV melanoma.
GetSignal Tempus AI Inc TEM
Tempus announced on October 7, 2026 an expanded, multi-year collaboration with Moderna and Merck.
Tempus said the collaboration supports the potential commercialization of intismeran autogene (V940/mRNA-4157), an individualized neoantigen therapy being evaluated in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with completely resected stage IIB-IV melanoma and other cancer types.
Key facts
- Date announced
- October 7, 2026
- Therapy
- Intismeran autogene (V940/mRNA-4157)
- Partners
- Moderna and Merck
- Indications under evaluation
- Completely resected stage IIB-IV melanoma and other cancer types
Source: The company's release on Business Wire, October 7, 2026.
Written by GetSignal with AI from the company's press release.
Not investment advice.
